Relay Therapeutics CEO Sanjiv Patel sells 48,202 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Relay Therapeutics, Inc. (RLAY) President and CEO Sanjiv Patel sold 48,202 shares at a weighted-average sale price of $16.13 per share on November 19, 2026; trades ranged from $15.89 to $16.72. The sale was under a Rule 10b5-1 trading plan adopted October 30, 2025. Patel directly held 423,099 shares after the sale. The Patel Family Irrevocable Trust of 2019 held 199,548 shares, and The SSP Irrevocable Trust of 2020 held 687,355. Both trusts benefit family members and have an independent trustee; Patel disclaims beneficial ownership.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 48,202 | $16.13 | $777K |
| Holding | Common Stock F3 | -- | -- | -- |
| Holding | Common Stock F3 | -- | -- | -- |
Footnotes (3)
- F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
- F2. This transaction was executed in multiple trades at prices ranging from $15.89 to $16.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3. These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average sale price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.